84138-86-3

Upstream product

• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 76902-49-3 N-(9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 73-03-0 cordycepin 
• 98-88-4 benzoyl chloride 
• 86234-44-8 (2R,3R,5S)-2-(6-Amino-purin-9-yl)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-tetrahydro-furan-3-ol 
• 207347-41-9 N-{9-[(2R,3R,5S)-5-((R)-1,2-Dihydroxy-ethyl)-3-hydroxy-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide 
• 207347-40-8 Acetic acid (2R,3R,5S)-2-(6-benzoylamino-purin-9-yl)-5-((R)-1,2-diacetoxy-ethyl)-tetrahydro-furan-3-yl ester 
• 4395-38-4 N₆,2',5'-tribenzoyl-3'-deoxyadenosine 

Downstream Products

• 138800-30-3 N⁶,O^2'-dibenzoyl-5'-(dimethoxytrityl)-3'-deoxyadenosine 
• 138824-83-6 Benzoic acid (2R,3R,5S)-5-[[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethoxy]-(2-cyano-ethoxy)-phosphanyloxymethyl]-2-(6-benzoylamino-purin-9-yl)-tetrahydro-furan-3-yl ester 
• 128893-74-3 N⁶,O^2'-dibenzoyl-3'-deoxyadenosine 
• 486424-66-2 N⁶-benzoyl-3'-deoxy-5'-O-(4,4'-dimethoxytrityl)-2'-adenylic acid 2-{[6-(benzoylamino)-9H-purin-9-yl]methoxy}ethyl 2-cyanoethyl ester 
• 486424-67-3 N⁶-benzoyl-3'-deoxy-2'-adenylic acid 2-{[6-(benzoylamino)-9H-purin-9-yl]methoxy}ethyl 2-cyanoethyl ester 
• 207347-42-0 N⁶-benzoyl-3'-deoxy-5'-O-(4,4'-dimethoxytrityl)adenosine 2'-(2-cyanoethyl diisopropylphosphoramidite) 

Relevant academic research and scientific papers

CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS

A class of polycyclic compounds of general formula (II), of general formula (II'), or of general formula (II"), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xsu

ANTIVIRAL PHOSPHINATE COMPOUNDS

A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administation of such compo

Inhibition of HIV-1 Replication by Chemically Synthesized, Nuclease-Resistant, Nontoxic (2'->5')-Oligoadenylate Agonists

The chemical syntheses of nuclease-resistant, nontoxic bioactive (2'-5')agonists, 3'-deoxyadenylyl-(2'->5')-3'-deoxyadenylyl-(2'->5')-3'-deoxyadenylyl-(2'->2")-9-[(2"-hydroxyethoxy)methyl]adenine (d3A-d3A-d3A-etherA; 36), 1-benzyl-3'-deoxyadenylyl-(2'->5')-3'-deoxyadenylyl-(2'->5')-3'-deoxyadenylyl-(2'->2")-9-[2"-hydroxyethoxy)methyl]adenine (N1-benzyl-d3A-d3A-d3A-etherA; 37), N6-benzyl-3'-deoxyadenylyl-(2'->5')-3'-deoxyadenylyl-(2'->5')-3'-deoxyadenylyl-(2'->2")-9-[(2"-hydroxyethoxy)methyl]adenine (N6-benzyl-d3A-d3A-d3A-etherA; 38), N6-benzyladenylyl-(2'->5')-adenylyl-(2'->5')-adenylyl-(2'->2")-9-[(2"-hydroxyethoxy)methyl]adenine (N6-benzyl-A-A-A-etheA; 39), as well as the biological activities of 37, 38, and already synthesized and published adenylyl-(2'->5')-adenylyl-(2'->5')-adenylyl-(2'->2")-9-[(2"-hydroxyethoxy)methyl]adenine (A-A-A-etherA; 40), are described. The above (2'-5')A derivatives 37-40 inhibit HIV-1 replication as measured by inhibition of syncytia formation, HIV-1 reverse transcriptase activity, or HIV-1 p24-antigen expression, with no evidence of cytotoxicity. Oligonucleotides 37, 38, and 40 were taken up intact into T cells in culture of cytoplasmic concentrations sufficient to activate the latent endoribonuclease, RNase L. N6-Benzyl-d3A-d3A-d3A-etherA (38) also exerts immunostimulatory effects by increasing expression of monocyte chemotactic protein-1 (MCP-1), and thereby, competing with HIV-1 for binding to a critical HIV-coreceptor.

Structurally altered substrates for DNA topoisomerase I. Effects of inclusion of a single 3'-deoxynucleotide within the scissile strand

A partial DNA duplex containing a high efficiency topoisomerase I cleavage site was substituted singly at each of three sites with 3'- deoxyadenosine. Depending on the site of substitution, the facility of the topoisomerase I-mediated cleavage or ligation